7.3 Generic Substitution & Biosimilar Interchange in Virginia

7.3 Generic Substitution & Biosimilar Interchange in Virginia

Generic drug substitution and biosimilar interchangeability are fundamental mechanisms designed to promote public healthcare affordability, enhance medication access, and preserve clinical efficacy. However, the authority to substitute an alternative product for a prescribed brand-name agent is strictly circumscribed by statute. In the Commonwealth of Virginia, the legal standards governing substitution are codified within the Virginia Drug Control Act at Code of Virginia § 54.1-3408.03, alongside federal evaluation standards established by the Food and Drug Administration (FDA).

On the Virginia MPJE, candidates are tested extensively on the exact statutory wording prescribers must use to prevent substitution, the legal invalidity of pre-printed check boxes, the structural taxonomy of the FDA Orange Book and FDA Purple Book, purchaser cost-savings pass-through mandates, container labeling rules, and the statutory 5-day prescriber notification window for interchangeable biologics.

---

Generic Substitution Framework (Code of Virginia § 54.1-3408.03)

Under Va. Code § 54.1-3408.03(A), a licensed pharmacist dispensing a prescription written for a brand-name drug product is statutorily authorized to dispense a generic drug product of established therapeutic equivalence, subject to specific prescriber and purchaser restrictions.

Virginia Generic Substitution Baseline Rules:
├── General Rule: Pharmacist MAY substitute a therapeutically equivalent generic product
├── Exception 1: Prescriber specifies Brand Medically Necessary in their own handwriting
└── Exception 2: Purchaser (patient) specifically requests the brand-name product

Prescriber Prohibition of Substitution

A pharmacist shall NOT substitute a generic product if the prescribing practitioner indicates that the brand name drug is medically necessary. Virginia statute establishes strict formatting requirements depending on the transmission medium:

1. Written Paper Prescriptions:
   • The prescriber must indicate that the brand product is necessary in their own handwriting by writing the words "Brand Medically Necessary", "Dispense as Written" (or "DAW"), or words of similar import directly onto the prescription blank.
   • The Pre-Printed Box Rule: Under Virginia law, pre-printed check boxes, pre-printed statements, or rubber-stamped notations indicating 'Dispense as Written' on a prescription blank are NOT legally effective to prohibit generic substitution, unless the prescriber specifically hand-initials or signs adjacent to the pre-printed box or statement. If a prescriber simply checks a pre-printed box labeled "DAW" without hand-initialing or handwriting the phrase, the pharmacist remains legally authorized to substitute a therapeutically equivalent generic!
2. Electronic Prescriptions (EPCS / e-Rx):
   • The prescriber must affirmatively select or populate the electronic prescribing field designating "Dispense as Written" or "Brand Medically Necessary".
3. Oral Prescriptions:
   • The prescriber or authorized agent must expressly state to the pharmacist during the telephone communication that the brand-name drug is medically necessary. The pharmacist must immediately record this specification on the written memorandum of the oral order.

Purchaser Notification and Cost-Savings Pass-Through

Under Va. Code § 54.1-3408.03(B), generic substitution is paired with mandatory consumer transparency and pricing protections:

• Mandatory Notification: The pharmacist must inform the purchaser (the patient or patient's agent presenting the prescription) that a generic drug substitution has been made.
• Purchaser Right of Refusal: The purchaser retains the absolute statutory right to refuse the generic substitute and demand the brand-name medication (subject to the patient assuming financial responsibility for any insurance price differential).
• Mandatory Savings Pass-Through: Virginia law explicitly mandates that any retail price difference (cost savings) between the brand-name product and the generic product dispensed must be passed on to the purchaser. A pharmacy cannot charge a consumer the full brand-name retail price when a lower-cost generic equivalent is dispensed.

Container Labeling for Generic Products

Under Va. Code § 54.1-3410 and Board regulation 18 VAC 110-20-340, when a generic medication is substituted, the prescription container label must clearly display:

1. The established generic name of the active drug;
2. The specific manufacturer or distributor of the generic product (or an approved packaging abbreviation); and
3. An optional bridging phrase clarifying substitution (e.g., "Atorvastatin 20 mg, generic for Lipitor").

---

The FDA Orange Book: Therapeutic Equivalence Codes

To be eligible for lawful generic substitution in Virginia without contacting the prescriber, a generic product must possess documented therapeutic equivalence to the prescribed reference listed drug (RLD). The official reference is the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations, universally known as the Orange Book.

Definition of Therapeutic Equivalence

Under federal FDA definitions, drug products are considered therapeutically equivalent only if they satisfy two rigorous criteria:

$\text{Therapeutic Equivalence} = \text{Pharmaceutical Equivalence} + \text{Bioequivalence}$

1. Pharmaceutical Equivalents: Drug products that contain identical amounts of the identical active drug ingredient, in the identical dosage form, administered by the identical route of administration, and meeting compendial standards for strength, quality, purity, and identity.
2. Bioequivalence: The absence of a significant difference in the rate and extent to which the active ingredient becomes available at the site of drug action when administered at the same molar dose under similar conditions.

The Orange Book Coding System

The Orange Book assigns two-letter equivalence codes. The first letter dictates whether the product is therapeutically equivalent:

Orange Book Equivalence Code Architecture:
├── "A" Codes ──► Therapeutically Equivalent to Reference Listed Drug (SUBSTITUTABLE in Virginia)
└── "B" Codes ──► NOT Therapeutically Equivalent; Bioequivalence Unresolved (CANNOT SUBSTITUTE)

The "A" Sub-Codes (Lawfully Substitutable in Virginia)

• AB: Products demonstrating bioequivalence through actual in vivo and/or in vitro scientific testing. In multi-source categories with multiple reference standards, numeric sub-codes are assigned (e.g., AB1, AB2, AB3). Products sharing the identical numeric sub-code (e.g., AB1 to AB1) are interchangeable; an AB1 product cannot be substituted for an AB2 reference without prescriber approval.
• AA: Conventional oral dosage forms that do not present known or suspected bioequivalence issues.
• AN: Aerosolized solutions, nebulizers, or dry powder inhalers meeting equivalence standards.
• AO: Injectable oil solutions.
• AP: Injectable aqueous solutions and intravenous admixtures.
• AT: Topical dermatological dosage forms meeting bioequivalence requirements.

The "B" Sub-Codes (NON-Substitutable in Virginia)

• B Codes (BD, BP, BX, BC, BS, BT): Products that the FDA does not consider therapeutically equivalent at this time. This includes drug products with unresolved bioequivalence problems (BP), active ingredients in dosage forms with documented bioequivalence discrepancies (BD), extended-release formulations lacking comparative bioavailability data (BC), or products with insufficient data to establish equivalence (BX).
• Virginia Practice Standard: In Virginia, a pharmacist CANNOT substitute a B-rated product for a brand-name drug without directly consulting the prescribing practitioner and obtaining express verbal or written authorization for a change in therapy. Dispensing a B-rated generic when a brand was prescribed constitutes misbranding and unauthorized dispensing.

Narrow Therapeutic Index (NTI) Drugs

Certain medications possess a narrow margin between therapeutic efficacy and lethal toxicity (e.g., warfarin, levothyroxine, digoxin, lithium, theophylline, phenytoin, carbamazepine). Under federal FDA standards, generic NTI products that achieve an AB rating are legally substitutable. While some states have enacted restrictive NTI non-substitution statutes, Virginia follows standard Orange Book equivalence: an AB-rated generic NTI drug may be lawfully substituted under § 54.1-3408.03, though professional guidelines recommend clinical monitoring and patient counseling upon formulation changes.

---

Biosimilar Interchangeability and the FDA Purple Book

Biologic medications—complex, large-molecule proteins derived from living organisms (e.g., monoclonal antibodies, insulins, receptor antagonists, colony-stimulating factors)—cannot be evaluated under traditional small-molecule Orange Book standards. Biologics are evaluated under the Biologics Price Competition and Innovation Act (BPCIA) and published in the FDA database Database of Licensed Biological Products, commonly known as the Purple Book.

FDA Biologic Classification Spectrum (The Purple Book):
├── Reference Product: The original innovator biologic approved under a 351(a) BLA (e.g., Humira)
├── Biosimilar: Highly similar with no clinically meaningful differences; NOT INTERCHANGEABLE
└── Interchangeable Biosimilar: Meets switching/alternating safety standards; SUBSTITUTABLE AT PHARMACY

The Crucial Legal Distinction: Biosimilar vs. Interchangeable Biosimilar

1. Biosimilar (Standard Biosimilar):
   • A biological product demonstrated to be "highly similar" to the reference product notwithstanding minor differences in clinically inactive components, with no clinically meaningful differences in safety, purity, and potency.
   • Pharmacy Law Restriction: A standard biosimilar CANNOT be substituted at the pharmacy level without prescriber intervention. A prescription written for "Humira" cannot be filled with a standard biosimilar unless the prescriber specifically wrote for the biosimilar by name or authorized the change.
2. Interchangeable Biosimilar:
   • A biosimilar that has met rigorous additional regulatory testing demonstrating that it can be expected to produce the same clinical result as the reference product in any given patient.
   • For products administered multiple times, studies must prove that alternating or switching between the reference product and the interchangeable biosimilar produces no heightened risk in terms of safety, immunogenicity, or diminished efficacy compared to continuous therapy with the reference product.
   • Pharmacy Law Authority: Under Va. Code § 54.1-3408.03(D), an interchangeable biosimilar MAY be substituted by the pharmacist for the reference product without prescriber authorization, exactly like an AB-rated small-molecule generic.

The Virginia 5-Business-Day Prescriber Notification Mandate

While an interchangeable biosimilar may be substituted without prior prescriber approval, the Commonwealth of Virginia imposes a strict post-dispensing communication mandate under Va. Code § 54.1-3408.03(D):

• Timeline: Within five (5) business days following the dispensing of a biological product, the dispensing pharmacist or their designee must communicate to the prescriber the specific product provided to the patient.
• Required Information: The communication must identify the exact biological product name and the manufacturer.
• Permissible Communication Mechanisms: The notification requirement is satisfied by entering the dispensing data into an electronic system that the prescriber can access, including:
  • An interoperable electronic health records (EHR) system;
  • An electronic prescribing platform;
  • A pharmacy benefit management (PBM) system; or
  • A direct facsimile (fax), electronic transmission, or telephone call.

Exceptions to the 5-Day Prescriber Notification Rule

Under Va. Code § 54.1-3408.03(D), prescriber notification is NOT required if:

1. There is no FDA-approved interchangeable biological product available, and the brand-name reference product was dispensed; or
2. The prescription is a refill, and the specific biological product dispensed (including manufacturer and formulation) is unchanged from the product dispensed on the most recent prior fill.

---

Comparison Summary: Orange Book vs. Purple Book Substitution in Virginia